
Carlos Malvestutto, MD, MPH
@dieguito99
Infectious Disease Doctor. HIV and COVID-19 Clinical Investigator. Triathlon enthusiast. 🇦🇷🇨🇦🇺🇸
ID: 40358611
15-05-2009 23:16:00
25 Tweet
174 Followers
507 Following

Leandro Mena discussing this morning the epidemic of HIV among AA MSM in the Southern US. Their lifetime risk of HIV is 50%. This is not acceptable! ncbi.nlm.nih.gov/m/pubmed/28325… @CDC_HIVAIDS HIV Medicine Association Jeanne Marrazzo

#IDWEEK2018 #IDSA Lynn Wardlow, PharmD Carlos Malvestutto, MD, MPH help us go viral! OSU ID and meningitis/encephalitis panel! Thanks to all the educators who help our fellows be the best! You know who you are!


#CROI2019 Point of care viral load testing in S Africa: 89.7% viral suppression and 99.8% of pts received VL results same day. Retention in care also was better. And patients liked it! Why aren’t we doing this in the US? In #ATL? HIV TaskForce Fulton



Great hearing from @DrDemetre (via Skype) on nychealthy’s efforts to end the HIV epidemic through testing, treatment and prevention through PrEP. #Gettested #UEqualsU



nytimes.com/2019/06/27/hea… via The New York Times


As ID physicians on the front line of combating the current global crisis, we stand strongly against President Donald J. Trump's decision to leave World Health Organization (WHO). We will not succeed against this pandemic, or any future outbreak, unless we stand together, share information, and coordinate actions.



“This is an exciting time, as Ohio State continues to lead the way to recovery for thousands of Ohioans impacted by the pandemic,” Dr. Malvestutto. Carlos Malvestutto, MD, MPH The Ohio State University Wexner Medical Center surpasses 1,100 monoclonal antibody infusions medicine.osu.edu/news/1100-mono…

A new REPRIEVE Trial manuscript examines ways in which sex and reproductive age are associated with levels of #immune markers such as #sCD14. More here: bit.ly/3CbtEdd NIAID News ACTG Network Harvard CBAR MassGeneral Medicine @nih_nhlbi Steve Grinspoon Pamela S Douglas Heather Ribaudo




Check out the new REPRIEVE Trial manuscript in Clinical Infectious Diseases examining #sexdifferences in systemic immune activation and #CAD among #peoplewithHIV. More here: bit.ly/3qAvgZa MassGeneral Medicine NIAID News @nih_nhlbi ACTG Network Harvard CBAR




